Clinical trial NCT00429923: Study of Difluprednate in the Treatment of Inflammation Following Ocular Surgery (ST-601A-002a)
Official title: A Phase 3 Multicenter, Randomized, Double-Masked, Placebo-Controlled Study of the Safety and Efficacy of Difluprednate in the Treatment of Inflammation Following Ocular Surgery
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Inflammation
Lead sponsor: Sirion Therapeutics, Inc.
Sponsor class: INDUSTRY
First posted: 2007-02-01
Enrollment: 219
Sex: ALL
Minimum age (years): 2
Standard ages: CHILD
ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The purpose of this phase III study is to determine the efficacy of difluprednate in the treatment of inflammation following ocular surgery.


Eligibility criteria: Inclusion Criteria:

* Unilateral ocular surgery in the day prior to study enrollment.
* Anterior chamber cell grade ≥ "2" on the day after surgery (Day 1).
* Aged 2 years or older on the day of consent.
* Negative urine pregnancy test on Day 1 for postmenarchal subjects; negative urine pregnancy test for premenarchal subjects at the investigator's discretion.
* Provide signed written consent prior to entering the study or signed written consent from parent or legal guardian if subject is a minor and signed assent from minor subject, if appropriate.

Presurgical Exclusion Criteria:

* Systemic administration of any corticosteroid in the 2 weeks prior to study enrollment.
* Periocular injection in the study eye of any corticosteroid solution within 4 weeks prior to instillation of the study drug, or of any corticosteroid depot within 2 months prior to instillation of the study drug.
* Instillation of any topical ocular corticosteroid or NSAID within 24 hours prior to instillation of the study drug or during the course of the study, with the exception of presurgical administration of a topical NSAID to prevent miosis.
* Any history of glaucoma or ocular hypertension in the study eye.
* History or presence of endogenous uveitis.
* Any current corneal abrasion or ulceration.
* Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease.
* Allergy to similar drugs, such as other corticosteroids.
* History of steroid-related IOP increase.
* Scheduled surgery on the contralateral eye during the treatment period.
* Unwilling to discontinue use of contact lenses during the study period.
* Pregnancy or lactation.
* Participation in any study of an investigational topical or systemic new drug or device within 30 days prior to screening, or at any time during the study.
* Prior participation in the study described in this protocol.
* Unable or unwilling to give signed informed consent prior to participation in any study related procedures.

Postsurgical Exclusion Criteria:

* Ocular hemorrhage which interferes with evaluation of postsurgery inflammation.
* Injection of gas into the vitreous body during surgery.
* Presence of IOP ≥24 mm Hg on Day 1 after surgery.

Primary outcomes:
measure: Anterior Chamber Cell Grade of "0" on Day 8 (Difluprednate QID vs Placebo).
timeFrame: Day 8 (QID)
Secondary outcomes:
Other outcomes:
Locations:
city: Washington
country: United States
facility: Comprehensive Eye Care
state: Missouri
Study officials:
affiliation: Sirion Therapeutics, Inc.
name: Roger Vogel, MD
role: STUDY_CHAIR
References:
citation: Korenfeld MS, Silverstein SM, Cooke DL, Vogel R, Crockett RS; Difluprednate Ophthalmic Emulsion 0.05% (Durezol) Study Group. Difluprednate ophthalmic emulsion 0.05% for postoperative inflammation and pain. J Cataract Refract Surg. 2009 Jan;35(1):26-34. doi: 10.1016/j.jcrs.2008.09.024.